Reviewing the Numbers on Shares of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA): Camarilla Pivot at 13.993333

Defining specific goals and creating an overall stock trading strategy can be a big help for the individual investor. Some investors are only interested in buy and hold strategies, while others will opt to try and capitalize on short-term market movements. Investors may also decide to do a little bit of both. They may choose a selection of stocks that they plan on holding for a long time, and they may choose others that they plan on holding for only a short period of time. Whichever way the investor decides to go, they should be prepared to complete all the research. Whether they want to study the fundamentals, technicals, or both, finding quality stocks may be at the forefront of the search.

Traders may be looking at some EMA levels on company shares. The exponential moving average can be very useful when applied correctly. They tend to work well when markets are trending. Here’s a look at some popular EMA levels for Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) :

50 day EMA: 14.071819
100 day EMA: 14.074556
200 day EMA: 13.925878
10 day EMA: 14.643537
20 day EMA: 14.385124
30 day EMA: 14.221131

Investors may be interested in the current Bull Bear Power reading on the stock which is currently at 0.573927. Investors may also be looking at some historical volatility numbers. Volatility for the month is presently 6.357856. Looking back for the previous week, volatility is 3.1546764.

Investors tracking shares of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) will note that the stock has seen a change of 0.06715917% since the open. Shares recently finished the previous session at 14.9. The one month high for the stock is currently standing at 15.05.

Technical stock analysts are always using every possible piece of information to help make the best possible trades. A popular flexible indicator is the Ichimoku Cloud. This indicator can help portray the momentum and trend direction of a stock. Ichimoku signals can help the trader find possible entry and exit points. Checking on some recent indicator levels, we note that the Ichimoku Could Conversion Line level is 14.49265, and the Ichimoku Cloud Base Line level is 13.81015. Tracking some variations, the Ichimoku Lead 1 is presently 14.0775, and the Lead 2 level is 13.88.

Switching the focus to the Awesome Oscillator, we see that the present reading is 0.6970403. Traders may be watching this oscillator to help identify a change in momentum. The AO can be a useful tool when trying to understand certain price movements.

Traders often use pivot point indicators when conducting technical stock analysis. Pivot points are commonly used to help identify trends of various time periods. Let’s check on some different one month pivot points:

Camarilla: 13.993333
Classic: 13.993333
Classic resistance 1: 14.966666
Classic support 1: 13.406667
Fibonacci: 13.993333
Fibonacci support 1: 13.397413
Fibonacci support 2: 13.029253
Woodie: 14.15
Woodie support 1: 13.72
Woodie resistance 1: 15.28

Traders may be keeping a close eye on shares of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Looking at past price performance may help them gauge how the stock will react in the future. Keeping in mind the most recent close price of 14.9, we note that the stock has seen a move of 3.6856744 over the previous week. Looking back out over the last month, the stock has moved 13.297873. Over the past three months, the stock has seen a change of -5.930599. Investors may want to go back even further to see what has transpired over a longer period of time. Since the start of the calendar year, shares have changed 65.11628. Going back a full 52 weeks, the stock has seen a change of 74.590164 over that period of time.

One of the biggest downfalls of the individual investor is not being able to take losses when it becomes necessary. Of course nobody wants to take a loss, but the repercussions of not letting go of a losing stock can end up sealing the demise of the well-intentioned investor. Many professionals would probably agree that the pain of realizing a loss is more intense than the joy of picking a winner. Investors who become reluctant to sell losers may be delaying the inevitable and essentially suffocating the portfolio. Not addressing the losing side can have severe negative effects on the long-term health of the portfolio. Investors may have to find a way to face the music and sell when they realize that a trade has gone sour.